

SUBJECT INDEX FOR SUPPLEMENT 2

Papers presented at the Symposium on Clinical Pharmacology, Jacksonville,
Florida, U.S.A. 12-13 March 1973

A

Actinomycin D,	
biochemical mechanisms of resistance	83
in combination chemotherapy	163
transport across cell membranes	47
Acute myelogenous leukemia,	
serum concentration of arabinosyl cytosine and therapeutic response	35
Adriamycin,	
cellular pharmacodynamics	207
in combination chemotherapy	163
of metastatic sarcomas	183
Alkylating agents,	
in combination chemotherapy	163
mechanisms of clinical resistance	83, 89
Amethopterin,	
toxicity in various species, relationship between concentration and time	35
Antineoplastic drugs,	
absorption, protein binding, distribution and excretion	9
in combination chemotherapy	129, 141
enzymatic activation and inactivation	71
factors affecting biotransformation and activity	21
mechanisms of resistance	83, 89
Antipurines,	
clinical resistance to	119
Antipyrимidine anticancer drugs,	
clinical resistance to	119
Arabinosyl cytosine,	
in combination chemotherapy	129, 141
cytokinetics	57
enzymatic activation and inactivation	71
mechanisms of resistance	83, 119
relationship between concentration and time, serum levels and biological response	35
Asparaginase,	
schedule-dependent synergism and antagonism with methotrexate	151
8-Azaguanine,	
mechanisms of resistance	83, 119
6-Azauridine,	
blood levels after oral or intravenous administration	9

B

Bleomycin,	
receptivity of target sites	193
treatment of bronchogenic carcinoma	177
Blood-brain barrier,	
to drugs	9
Blood-brain-CSF exchange,	
of antitumour agents	51
Bone marrow,	
descriptive and operational cytokinetics	57
Brain tumour,	
chemotherapy	51
Busulphan,	
mechanisms of clinical resistance	89

C

Camptothecin,	
plasma protein binding	9
Central nervous system tumours,	
chemotherapy	51
Chemotherapy,	
general mechanisms of clinical resistance	83
Chlorambucil,	
mechanisms of clinical resistance	89
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea,	
in combination therapy	163
reactions and effects of	225
1,3-bis(2-Chloroethyl)-1-nitrosourea,	
in combination therapy with cyclophosphamide	163
reactions and effects of	225
1-(2-Chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea,	
in combination chemotherapy of lung cancer	177
reactions and effects of	225
5-[3,3-bis(2-Chloroethyl)-1-triazeno]imidazole-4-carboxamide,	
in combination therapy	163
Circadian rhythmicity,	
of drug metabolism in rats	21
Clinical resistance,	
to alkylating agents	89
to antipyrimidine anticancer drugs	119
biochemical mechanisms	83
to folic acid antagonists	101
to purine analogues	107
Combination chemotherapy,	
in animal models	141
biochemical and pharmacological principles	129
of metastatic sarcomas using adriamycin	183
new combinations in the treatment of lung cancer	177
new experimental drug combinations	163
schedule-dependent synergism and antagonism between methotrexate and asparaginase	151
Cyclophosphamide,	
in combination chemotherapy	163
of lung cancer	177
enzymatic activation and inactivation	71
mechanisms of clinical resistance	89
pharmacokinetic parameters and leukopenic activity in mice	21
toxicity in various species, relationship between concentration and time	35
Cytokinetics,	
of chemotherapy, descriptive and operational approaches	57
Cytotoxicity,	
relationship of concentration and time	35

D

Daunomycin,	
biochemical mechanisms of resistance	83
combination therapy	141
Daunorubicin,	
cellular pharmacodynamics	207
Deoxyribonucleic acid,	
synthesis in L1210 cells, effect of adriamycin and daunorubicin	207
Deoxyribonucleic acid binding drugs,	
in combination chemotherapy	163
cis-Diamminedichloroplatinum,	
in combination therapy with 5-fluorouracil	163
3',5'-Dichloromethotrexate,	
mechanisms of resistance	119
Dimethyl-triazeno-imidazole carboxamide,	
in combination with adriamycin in the treatment of metastatic sarcomas	183
cytotoxicity	21
enzymatic activation and inactivation	71

Drug selectivity, in cancer chemotherapy, role of enzymatic activation and inactivation	71
E	
Enzymatic activation and inactivation, role in drug selectivity	71
F	
5-Fluorouracil, biochemical mechanisms of resistance	83, 119
clinical resistance to	119
in combination chemotherapy with <i>cis</i> -diamminedichloro-platinum	163
Folic acid antagonists, resistance to	101
H	
Hydrocortisone, circadian rhythmicity in rats	21
I	
Immunosuppressive activity, effect of phenobarbital	21
Intestinal epithelium, descriptive and operational cytokinetics	57
L	
Leukemia L1210, combination therapy with <i>cis</i> -diamminedichloroplatinum	163
examples of therapeutic synergism against	141
pharmacodynamics of adriamycin and daunorubicin	207
Leukemia L5178Y, synergism and antagonism between methotrexate and asparaginase	151
Lung cancer, combination chemotherapy	177
M	
Melphan, mechanisms of clinical resistance	89
Membrane transport, of tumour-inhibiting agents	47
6-Mercaptopurine, circadian rhythmicity and immunosuppressive activity in rats	21
in combination chemotherapy	129, 141
enzymatic activation and in activation	71
mechanisms of resistance	83, 107, 119
toxicity in various species, relationship of concentration and time	35
Metastatic sarcomas, chemotherapy using combinations with adriamycin	183
Methotrexate, absorption, protein binding, distribution and excretion	9
in combination therapy	129
synergism and antagonism with asparaginase	151
kinetics and effect	1
mechanisms of resistance	83, 101 119
transport across cell membranes	47
N-Methylnitrosourea, tumour responsiveness <i>in vivo</i>	21
Microtubule system, effect of vinca alkaloids	217

N

Nitrogen mustards, mechanisms of clinical resistance	89
Nitrosoureas, reactions and effects of	225

P

Pharmacokinetic models,	1
Phenobarbital, effect on immunosuppressive and antitumoural activities of cyclophosphamide in mice	21
Phleomycin, receptivity of target sites	193
Protein binding, of antineoplastic drugs	9
Purine analogues, resistance to	107
Purines and pyrimidines, biochemical mechanisms of resistance in animal tumours	83
Purine and pyrimidine antimetabolites, enzymatic activation and in activation	71

T

Terephthalanilide, biochemical mechanisms of resistance	83
Testes, drug uptake	9
6-Thioguanine, biochemical mechanisms of resistance	83
6-Thiopurines, resistance to	107
Thymidine, cytotoxic effects compared with arabinosyl cytosine	57
Triamterene, mechanisms of resistance	119
N,N',N''-Triethylenethiophosphoramidate, mechanisms of clinical resistance	89
Tumours, in the CNS, chemotherapy descriptive and operational cytogenetics drug responsiveness <i>in vivo</i>	51 57 21
Tumour-inhibitory agents, transport across cell membranes	47

V

Vinblastine, biochemical mechanisms of resistance distribution and interactions in body compartments	83 217
Vincristine, biochemical mechanisms of resistance in combination chemotherapy of lung cancer in combination chemotherapy of metastatic sarcomas distribution and interactions in body compartments	83 177 183 217

Z

Zoxazolamine, metabolism <i>in vivo</i> in normal and Walker carcinoma-bearing rats	
---	--